Pancreatic DiseasesLast update of the site: Wednesday March 06, 2024
Mark Conor
Harris
et al. | ANZ Journal of Surgery 2024; AOP: 10.1111/ans.18903...
High recurrence rate limits long‐term survival after pancreatic cancer surgery and represents a major clinical challenge in the management of patients...
Abe Shohei et al. | Journal of Gastroenterology 2024; 59(3):...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal human cancers, with a 5-year survival rate of less than 10% [1]. PDAC...
Kashiro Ayumi et al. | Journal of Gastroenterology 2024; 59(3):...
To reduce the mortality of patients diagnosed with pancreatic cancer, there is an urgent need for non-invasive screening methods using circulating blood...
Bibliographical searchFocus and target to your research of scientific data
Top articlesThe 5 most read articles
Mark Conor
Harris
et al. | ANZ Journal of Surgery 2024; AOP: 10.1111/ans.18903...
High recurrence rate limits long‐term survival after pancreatic cancer surgery and represents a major clinical challenge in the management of patients with pancreatic malignancies. This emphasizes...
Abe Shohei et al. | Journal of Gastroenterology 2024; 59(3):...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal human cancers, with a 5-year survival rate of less than 10% [1]. PDAC progression and metastasis are not solely determined...
Kashiro Ayumi et al. | Journal of Gastroenterology 2024; 59(3):...
To reduce the mortality of patients diagnosed with pancreatic cancer, there is an urgent need for non-invasive screening methods using circulating blood biomarkers for pancreatic cancer. Carbohydrate antigen...
Basnet Angisha et al. | Cancer Immunology, Immunotherapy 2024;...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer diagnoses, with less than 12% of patients surviving 5 years after detection [1]. Normally diagnosed at late stages, PDAC is...
Ji Hyun
Park
et al. | Histopathology 2024; AOP: 10.1111/his.15154...
Tumour budding has been recognized as a prognostic biomarker, but except for colorectal cancer, its clinical application has been limited by a lack of evidence and standardized scoring criteria.
This study...
Communicate!
You find this service useful for your professional practice? Inform a colleague about the platform.